RU2291710C2 - Комбинированное лекарственное средство для лечения опухолевых заболеваний - Google Patents

Комбинированное лекарственное средство для лечения опухолевых заболеваний Download PDF

Info

Publication number
RU2291710C2
RU2291710C2 RU2003137006/15A RU2003137006A RU2291710C2 RU 2291710 C2 RU2291710 C2 RU 2291710C2 RU 2003137006/15 A RU2003137006/15 A RU 2003137006/15A RU 2003137006 A RU2003137006 A RU 2003137006A RU 2291710 C2 RU2291710 C2 RU 2291710C2
Authority
RU
Russia
Prior art keywords
cancer
cyano
use according
pyridyl
guanidine
Prior art date
Application number
RU2003137006/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2003137006A (ru
Inventor
Лизе БИНДЕРУП (DK)
Лизе БИНДЕРУП
Эрик БРАММ (DK)
Эрик БРАММ
Пернилле-Юли Виг ЯРНО (DK)
Пернилле-Юлия Виг ЯРНО
Карин Екснер ХАМБЕРГ (DK)
Карин Екснер ХАМБЕРГ
Original Assignee
Лео Фарма А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лео Фарма А/С filed Critical Лео Фарма А/С
Publication of RU2003137006A publication Critical patent/RU2003137006A/ru
Application granted granted Critical
Publication of RU2291710C2 publication Critical patent/RU2291710C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2003137006/15A 2001-05-24 2002-05-24 Комбинированное лекарственное средство для лечения опухолевых заболеваний RU2291710C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29292801P 2001-05-24 2001-05-24
US60/292,928 2001-05-24

Publications (2)

Publication Number Publication Date
RU2003137006A RU2003137006A (ru) 2005-04-10
RU2291710C2 true RU2291710C2 (ru) 2007-01-20

Family

ID=23126850

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003137006/15A RU2291710C2 (ru) 2001-05-24 2002-05-24 Комбинированное лекарственное средство для лечения опухолевых заболеваний

Country Status (17)

Country Link
US (1) US20030045515A1 (https=)
EP (1) EP1411984B1 (https=)
JP (1) JP2005508857A (https=)
KR (1) KR20040007607A (https=)
CN (1) CN1516600A (https=)
AT (1) ATE394100T1 (https=)
AU (1) AU2002316795B2 (https=)
BR (1) BR0209936A (https=)
CA (1) CA2449442A1 (https=)
CZ (1) CZ20033189A3 (https=)
DE (1) DE60226446D1 (https=)
HU (1) HUP0400024A3 (https=)
IL (1) IL158821A0 (https=)
MX (1) MXPA03010691A (https=)
PL (1) PL366462A1 (https=)
RU (1) RU2291710C2 (https=)
WO (1) WO2002094322A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2485351C (en) * 2002-05-17 2011-12-06 Leo Pharma A/S Cyanoguanidine prodrugs
US7253193B2 (en) * 2002-05-17 2007-08-07 Leo Pharma A/S Cyanoguanidine prodrugs
CA2484671A1 (en) * 2002-05-17 2003-11-27 Leo Pharma A/S Cyanoguanidine prodrugs
JP2006512313A (ja) 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
WO2004047673A2 (en) * 2002-11-21 2004-06-10 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
US20050075341A1 (en) * 2003-07-17 2005-04-07 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
JP5189367B2 (ja) * 2004-12-22 2013-04-24 レオ ファーマ アクティーゼルスカブ 新規シアノグアニジン化合物
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
NZ563687A (en) 2005-06-30 2011-07-29 Smithkline Beecham Corp 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[2-(1-methylethyl)-2,3-dihydro-1H-isoindol-5-yl]-1H-indole-7-carboxamide for inhibiting IKK2 (aka IKKbeta)
JP2009502996A (ja) * 2005-08-04 2009-01-29 バイエル・ヘルスケア・アクチェンゲゼルシャフト ＩＫＫ−β阻害剤との組合せ
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
KR20130097813A (ko) 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
EP2394649A4 (en) * 2009-02-06 2012-08-15 Tianjin Hemay Bio Tech Co Ltd PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDYL-CYANOGUANIDINES, PREPARATION METHODS AND USES THEREOF
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
CN106243023A (zh) 2010-09-03 2016-12-21 福马Tm有限责任公司 用于抑制nampt的胍化合物和组合物
CN108779073A (zh) * 2015-06-23 2018-11-09 凯斯西储大学 用于治疗癌症的组合物和方法
JP7033789B2 (ja) 2016-06-29 2022-03-11 オトノミー，インク． トリグリセリド耳用製剤とその使用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002183A1 (fr) * 1996-07-15 1998-01-22 Sankyo Company, Limited Compositions medicinales
WO1998054143A1 (en) * 1997-05-29 1998-12-03 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Cyanoguanidines as cell proliferation inhibitors
WO1998054141A1 (en) * 1997-05-29 1998-12-03 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Cyanoguanidines as cell proliferation inhibitors
RU2141951C1 (ru) * 1992-09-15 1999-11-27 Лео Фармасьютикал Продактс Лтд. А/С (Левенс Кемиске Фабрик Продукционсактиесельскаб) N-циано-n'-пиридилгуанидины, или их n-оксиды, или их фармацевтически приемлемые нетоксичные соли, способы их получения, фармацевтическая композиция и способ ингибирования пролиферации опухолевых клеток
RU99103215A (ru) * 1996-07-15 2000-12-10 Санкио Компани Лимитед Фармацевтическая композиция

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9711122D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711125D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711124D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
AU1494702A (en) * 2000-11-21 2002-06-03 Leo Pharma As Cyanoguanidine prodrugs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2141951C1 (ru) * 1992-09-15 1999-11-27 Лео Фармасьютикал Продактс Лтд. А/С (Левенс Кемиске Фабрик Продукционсактиесельскаб) N-циано-n'-пиридилгуанидины, или их n-оксиды, или их фармацевтически приемлемые нетоксичные соли, способы их получения, фармацевтическая композиция и способ ингибирования пролиферации опухолевых клеток
WO1998002183A1 (fr) * 1996-07-15 1998-01-22 Sankyo Company, Limited Compositions medicinales
RU99103215A (ru) * 1996-07-15 2000-12-10 Санкио Компани Лимитед Фармацевтическая композиция
WO1998054143A1 (en) * 1997-05-29 1998-12-03 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Cyanoguanidines as cell proliferation inhibitors
WO1998054141A1 (en) * 1997-05-29 1998-12-03 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Cyanoguanidines as cell proliferation inhibitors

Also Published As

Publication number Publication date
HUP0400024A2 (hu) 2004-04-28
HUP0400024A3 (en) 2007-05-29
KR20040007607A (ko) 2004-01-24
WO2002094322A2 (en) 2002-11-28
CZ20033189A3 (cs) 2004-12-15
ATE394100T1 (de) 2008-05-15
AU2002316795B2 (en) 2007-08-02
DE60226446D1 (de) 2008-06-19
CA2449442A1 (en) 2002-11-28
EP1411984B1 (en) 2008-05-07
PL366462A1 (en) 2005-02-07
US20030045515A1 (en) 2003-03-06
CN1516600A (zh) 2004-07-28
JP2005508857A (ja) 2005-04-07
EP1411984A2 (en) 2004-04-28
WO2002094322A3 (en) 2004-02-26
IL158821A0 (en) 2004-05-12
RU2003137006A (ru) 2005-04-10
BR0209936A (pt) 2004-04-06
MXPA03010691A (es) 2004-07-01

Similar Documents

Publication Publication Date Title
RU2291710C2 (ru) Комбинированное лекарственное средство для лечения опухолевых заболеваний
AU2002316795A1 (en) Combination medicament for treatment of neoplastic diseases containing cyanoguanidine IKK inhibitors and a second anti-neoplastic drug
JP5075927B2 (ja) 固形腫瘍を予防および治療するための方法および組成物
JP5795714B2 (ja) アレナウイルス感染症の治療のための抗ウイルス薬
RU2292344C2 (ru) Производные пиридилцианогуанидинов и фармацевтическая композиция на их основе
US20160287564A1 (en) Methods of administering glutaminase inhibitors
WO2015138902A1 (en) Combination therapy with glutaminase inhibitors
WO2017042944A1 (ja) フィラデルフィア染色体陽性（Ｐｈ＋）急性リンパ性白血病（ＡＬＬ）の治療薬又は治療方法
JP2012500809A (ja) 免疫調節活性
WO2002094265A1 (en) A method of modulating nf-$g(k)b activity
US20250144079A1 (en) Methods of inhibiting tumor metastasis
TWI355935B (en) Combination of a taxane and a cyclin-dependent kin
US6642215B2 (en) Method of modulating NF-kB activity
CN109528731A (zh) 具有协同作用治疗多发性骨髓瘤的药物组合物及其应用
KR101916283B1 (ko) 암에 대한 방사선 치료 증진용 약학적 조성물
CN115969975A (zh) Phgdh抑制剂在预防和/或治疗结直肠癌转移中的应用
HK1065260A (en) Combination medicament for treatment of neoplastic diseases
US10512630B2 (en) Compositions and methods for treating cancer
AU784523B2 (en) Treatment of lymphomas, leukemias, breast carcinomas, astrocytomas, melanomas, leiomyomas, and related tumors
RU2279277C2 (ru) Лечение разделенными дозами агентов с сосудоразрушающей активностью
CN121197172A (zh) 化合物kh16在制备预防或治疗巴贝斯虫病药物中的应用
WO2025241125A1 (zh) 度洛西汀及化疗药物用于制备用于治疗或预防癌症的医药组成物的用途
CN120754119A (zh) 安石榴甙与奥沙利铂组合在制备胃癌卵巢转移的治疗药物中的应用
CN121534070A (zh) 乔松素衍生物在制备抗肿瘤药物中的应用
CN120919304A (zh) 一种治疗三阴性乳腺癌的药物组合物及其应用

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20080525